{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regranex%C2%AE",
    "query": {
      "intervention": "Regranex®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T08:03:39.174Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01305356",
      "title": "Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Degenerative Joint Disease",
        "Congenital Deformity",
        "Arthritis",
        "Osteoarthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Augment® Injectable Bone Graft",
          "type": "DEVICE"
        },
        {
          "name": "Autologous bone graft",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "BioMimetic Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 299,
      "start_date": "2011-03",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2018-12-26",
      "last_synced_at": "2026-09-05T08:03:39.174Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305356"
    },
    {
      "nct_id": "NCT00389636",
      "title": "TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer"
      ],
      "interventions": [
        {
          "name": "TheraGauze",
          "type": "DEVICE"
        },
        {
          "name": "Regranex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Solsys Medical LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-09",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2008-05-07",
      "last_synced_at": "2026-09-05T08:03:39.174Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389636"
    },
    {
      "nct_id": "NCT00446472",
      "title": "Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcers"
      ],
      "interventions": [
        {
          "name": "Regranex®",
          "type": "DRUG"
        },
        {
          "name": "Hydrogel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California Institute for Research and Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-04",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2010-06-04",
      "last_synced_at": "2026-09-05T08:03:39.174Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • Los Angeles, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446472"
    },
    {
      "nct_id": "NCT02387957",
      "title": "A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Fovista®",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2016-04-26",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-30",
      "last_synced_at": "2026-09-05T08:03:39.174Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "New London",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02387957"
    },
    {
      "nct_id": "NCT02214628",
      "title": "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Fovista® (anti-PDGF BB) plus anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2014-07",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-09-05T08:03:39.174Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214628"
    }
  ]
}